These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25477091)

  • 21. [Melanoma].
    Uhara H
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
    Seghers AC; Wilgenhof S; Lebbé C; Neyns B
    Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
    Atkins MB
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):417-9. PubMed ID: 27379810
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.
    Kudchadkar R; Paraiso KH; Smalley KS
    Cancer J; 2012; 18(2):124-31. PubMed ID: 22453012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
    Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
    Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein kinase inhibitors in melanoma.
    Eigentler TK; Meier F; Garbe C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2195-201. PubMed ID: 23992377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of a patient with advanced BRAF-mutant melanoma.
    Ashworth MT; Daud A
    J Natl Compr Canc Netw; 2014 Mar; 12(3):315-9; quiz 319. PubMed ID: 24616537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
    Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
    Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [BRAF inhibitor and MEK inhibitor].
    Uhara H
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
    [No Abstract]   [Full Text] [Related]  

  • 32. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K
    Pires da Silva I; Wang KYX; Wilmott JS; Holst J; Carlino MS; Park JJ; Quek C; Wongchenko M; Yan Y; Mann G; Johnson DB; McQuade JL; Rai R; Kefford RF; Rizos H; Scolyer RA; Yang JYH; Long GV; Menzies AM
    Clin Cancer Res; 2019 Feb; 25(4):1272-1279. PubMed ID: 30630828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.
    Rizzo D; Ruggiero A; Amato M; Maurizi P; Riccardi R
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1397-1405. PubMed ID: 27494648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.
    Flaherty K
    Clin Adv Hematol Oncol; 2017 Oct; 15(10):745-747. PubMed ID: 29040252
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and tolerance of BRAF and MEK inhibitors on metastatic melanoma carrying the orphan pV600_K601 delinsE mutation of the BRAF gene.
    Barbé J; Garnier M; Tallet A; Collin C; Leducq S; Routier É; Machet L; Samimi M
    Int J Dermatol; 2021 Jul; 60(7):e283-e284. PubMed ID: 33734441
    [No Abstract]   [Full Text] [Related]  

  • 37. Discovery and pharmacophore studies of novel pyrazole-based anti-melanoma agents.
    Li QS; Lü XH; Yang Y; Ruan BF; Yao RS; Liao CZ
    Chem Biodivers; 2015 Jan; 12(1):116-32. PubMed ID: 25641840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Protein kinase inhibitors can induce retinopathy].
    Lindboe JB; Ahmed HJ; Christakopoulos CE
    Ugeskr Laeger; 2020 Aug; 182(32):. PubMed ID: 32800052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapies for treating metastatic melanoma.
    Tawbi H
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):211-4. PubMed ID: 26352577
    [No Abstract]   [Full Text] [Related]  

  • 40. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
    Wilson MA; Zhao F; Khare S; Roszik J; Woodman SE; D'Andrea K; Wubbenhorst B; Rimm DL; Kirkwood JM; Kluger HM; Schuchter LM; Lee SJ; Flaherty KT; Nathanson KL
    Clin Cancer Res; 2016 Jan; 22(2):374-82. PubMed ID: 26307133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.